Cargando…

A dual MET/AXL small‐molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment

The receptor tyrosine kinases MET and AXL have been implicated in tumorigenesis and aggressiveness of multiple malignancies. We performed this study to evaluate the antitumor impact of LY2801653, a dual MET and AXL inhibitor on gastric cancer and to elucidate the underlying mechanisms. In the presen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Chenjing, Shi, Huashan, Wu, Min, Wei, Xiawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489669/ https://www.ncbi.nlm.nih.gov/pubmed/34766112 http://dx.doi.org/10.1002/mco2.11

Ejemplares similares

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
por: Zhu, Chenjing, et al.
Publicado: (2019)

First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer
por: Hu, Xingsheng, et al.
Publicado: (2020)

Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
por: Lauter, Markus, et al.
Publicado: (2019)

Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control
por: Pyo, Kyoung-Ho, et al.
Publicado: (2023)

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
por: Kwilas, Anna R, et al.
Publicado: (2014)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

Targeting Tumor Microenvironment by Small-Molecule Inhibitors
por: Zhong, Shangwei, et al.
Publicado: (2019)

Reprogramming the immunological microenvironment through radiation and targeting Axl
por: Aguilera, Todd A., et al.
Publicado: (2016)

Effects of Cabozantinib, a small molecule tyrosine kinase inhibitor, on the immune permissiveness of the tumor microenvironment and immune-mediated killing of tumor cells
por: Kwilas, Anna R, et al.
Publicado: (2014)

Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment
por: Wang, Kai-Hung, et al.
Publicado: (2020)

Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
por: Hsu, Jeff, et al.
Publicado: (2023)

Axl, Immune Checkpoint Molecules and HIF Inhibitors from the Culture Broth of Lepista luscina
por: Kotajima, Mihaya, et al.
Publicado: (2022)

Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment
por: Tanaka, Mai, et al.
Publicado: (2020)

Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors
por: Nishio, Makoto, et al.
Publicado: (2022)

Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
por: Onken, Julia, et al.
Publicado: (2016)

Marsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells
por: Han, Shu-Yan, et al.
Publicado: (2017)

Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
por: Zhang, Qian, et al.
Publicado: (2020)

A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
por: Rios-Doria, Jonathan, et al.
Publicado: (2020)

NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells
por: de Miranda, Lívia Bassani Lins, et al.
Publicado: (2022)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis
por: Hsu, Tung-Wei, et al.
Publicado: (2023)

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy
por: Oien, Derek B., et al.
Publicado: (2018)

Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression
por: Umemura, Shiori, et al.
Publicado: (2020)

Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor
por: Lee, Ho Jin, et al.
Publicado: (2021)

Inhibition of A20 expression in tumor microenvironment exerts anti-tumor effect through inducing myeloid-derived suppressor cells apoptosis
por: Shao, Bin, et al.
Publicado: (2015)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274
por: Hou, Jinxuan, et al.
Publicado: (2011)

Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells
por: Vouri, Mikaella, et al.
Publicado: (2015)

MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?
por: El Darsa, Haidar, et al.
Publicado: (2020)

Implications of the Receptor Tyrosine Kinase Axl in Gastric Cancer Progression
por: He, Lirui, et al.
Publicado: (2020)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
por: Hagege, Anais, et al.
Publicado: (2022)

AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma
por: Zito Marino, Federica, et al.
Publicado: (2022)

Elevated Levels of Soluble Axl (sAxl) Regulates Key Angiogenic Molecules to Induce Placental Endothelial Dysfunction and a Preeclampsia-Like Phenotype
por: Gui, Shunping, et al.
Publicado: (2021)

Author Correction: Inhibition of A20 expression in tumor microenvironment exerts anti-tumor effect through inducing myeloid-derived suppressor cells apoptosis
por: Shao, Bin, et al.
Publicado: (2023)

Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
por: Phillip, Cornel Joseph, et al.
Publicado: (2013)

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
por: Crosswell, Hal E, et al.
Publicado: (2009)

Study of Optimal Cam Design of Dual-Axle Spring-Loaded Camming Device
por: Rybansky, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_abo7bjrnugp37tlnlrl3urlqsv